Adavivint (SM04690) (Synonyms: SM04690; Lorecivivint) |
カタログ番号GC31663 |
アダビビント (SM04690) (SM04690; Lorecivivint) は、標準的な Wnt シグナル伝達の強力かつ選択的な阻害剤であり、SW480 結腸癌細胞におけるハイスループット TCF/LEF レポーターアッセイによる EC50 は 19.5 nM です。
Products are for research use only. Not for human use. We do not sell to patients.
Cas No.: 1467093-03-3
Sample solution is provided at 25 µL, 10mM.
Adavivint is a potent and selective inhibitor of canonical Wnt signaling, with an EC50 of 19.5 nM via a high-throughput TCF/LEF-reporter assay in SW480 colon cancer cells.
Adavivint (SM04690) is a potent and selective inhibitor of Wnt signaling, with an EC50 of 19.5 nM via a high-throughput TCF/LEF-reporter assay in SW480 colon cancer cells, and shows no effect on SV40 luciferase reporter. Adavivint enhances aggregation of human mesenchymal stem cells (hMSCs) with an EC50 of 10 nM. Adavivint (30 nM) protects chondrocytes from catabolic breakdown in vitro[1].
Adavivint (0.3 μg) enhances cartilage repair and protection in the rat acute cruciate ligament tear and partial medial meniscectomy osteoarthritis (ACLT + pMMx OA) model[1].
[1]. Deshmukh V, et al. A small-molecule inhibitor of the Wnt pathway (SM04690) as a potential disease modifying agent for the treatment of osteoarthritis of the knee. Osteoarthritis Cartilage. 2018 Jan;26(1):18-27.
Average Rating: 5
(Based on Reviews and 6 reference(s) in Google Scholar.)GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.
Required fields are marked with *